Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 792 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 792 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $146.04, for a total transaction of $115,663.68. Following the completion of the transaction, the chief financial officer now owns 71,869 shares in the company, valued at $10,495,748.76. The trade was a 1.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Stock Up 3.1 %

Shares of NTRA stock opened at $150.87 on Thursday. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The stock has a market cap of $20.40 billion, a P/E ratio of -85.72 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a 50 day simple moving average of $162.25 and a two-hundred day simple moving average of $149.27.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTRA. Barclays began coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price on the stock. Morgan Stanley upped their target price on shares of Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. The Goldman Sachs Group upped their target price on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Sanford C. Bernstein upped their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Finally, Piper Sandler increased their price objective on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $178.12.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock worth $1,949,697,000 after purchasing an additional 879,463 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock worth $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Natera by 15.7% in the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company’s stock worth $512,898,000 after purchasing an additional 439,778 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Natera by 3.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after purchasing an additional 85,236 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.